Details for New Drug Application (NDA): 213517
✉ Email this page to a colleague
The generic ingredient in RANOLAZINE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 213517
| Tradename: | RANOLAZINE |
| Applicant: | I3 Pharms |
| Ingredient: | ranolazine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 213517
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 213517 | ANDA | Bryant Ranch Prepack | 71335-2556 | 71335-2556-1 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (71335-2556-1) |
| RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 213517 | ANDA | i3 Pharmaceuticals, LLC | 72319-021 | 72319-021-02 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (72319-021-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
| Approval Date: | Apr 27, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
| Approval Date: | Apr 27, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
